PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2012Circulation Journal646 citationsOpen Access

Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation

MHMasatsugu HoriMMMasayasu MatsumotoNTNorio Tanahashi

Key Points

  • To assess the safety of a Japan-specific dose of rivaroxaban in atrial fibrillation patients.
  • Conducted within the J-ROCKET AF trial framework

Structured PICO

Does a Japan-specific rivaroxaban dose demonstrate safety compared to warfarin in Japanese patients with atrial fibrillation?

P
Population
Japanese patients with atrial fibrillation
I
Intervention
Japan-specific rivaroxaban dose
C
Comparator
Warfarin
O
Outcome
Safetysafety

A Japan-specific dose of rivaroxaban is safe in Japanese patients with atrial fibrillation, supporting the applicability of global ROCKET AF results to this population.

Abstract

J-ROCKET AF demonstrated the safety of a Japan-specific rivaroxaban dose and supports bridging the global ROCKET AF results into Japanese clinical practice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hori et al. (2012) studied this question.

synapsesocial.com/papers/69952def9c43653a44f03cafhttps://doi.org/10.1253/circj.cj-12-0454
Ask AI
Helpful
Bookmark
Share
View Full Paper